The Unified Patent Court (UPC) Court of Appeal granted Abbott (NYSE:ABT) a preliminary injunction in its patent battle against Sinocare. Abbott’s preliminary injunction victory means Sinocare is banned from selling its iCan i3 continuous glucose monitor (CGM) offering in UPC territory. The UPC decision overturned a prior ruling from a local division (LD) of The […]
sinocare
Sinocare withdraws FDA submission for CGM to focus on next-gen system
Sinocare announced recently that it withdrew its FDA submission for the first-generation iCan i3 continuous glucose monitor (CGM). The company withdrew the FDA 510(k) submission as it looks to instead expedite bringing its next-gen solution to the market. China-based Sinocare designed the iCan i3 CGM for ease of use, with no scanning, no fingersticks and […]
Sinocare prevails in CGM trademark spat with Abbott
Sinocare announced recently that it successfully defended itself in court against trademark infringement claims brought by Abbott (NYSE:ABT). The China-based continuous glucose monitor (CGM) maker defended itself in the High Court of Justice (Chancery Division) of England and Wales against claims regarding trademark infringement and passing off. Abbott claimed that Sinocare’s iCan i3 CGM system […]
Report: Chinese bidders eye Johnson & Johnson’s diabetes biz
Chinese glucose monitor maker Sinocare (SZ:300298) and a sovereign wealth fund there are said to be in the hunt for the diabetes business Johnson & Johnson (NYSE:JNJ) is looking to unload. The New Brunswick, N.J.-based healthcare conglomerate early last year announced a strategic review of its LifeScan, Animas and Calibra Medical diabetes businesses and later elected to […]
